Press release
Hypercholesterolemia Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore our latest breakthroughs in Hypercholesterolemia Research. Learn more about our innovative pipeline today! @ Hypercholesterolemia Pipeline Outlook [https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hypercholesterolemia Pipeline Report
* In July 2025, Merck Sharp & Dohme LLC announced a study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).
* DelveInsight's Hypercholesterolemia pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Hypercholesterolemia treatment.
* The leading Hypercholesterolemia Companies such as Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics and others.
* Promising Hypercholesterolemia Pipeline Therapies such as Gemcabene, Rosuvastatin calcium, KJX839, statins, ezetimibe, MK-0524A, ER Niacin and others.
Stay informed about the cutting-edge advancements in Hypercholesterolemia treatments. Download for updates and be a part of the revolution in Cardiovascular Diseases Care @ Hypercholesterolemia Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hypercholesterolemia Emerging Drugs Profile
* MK-0616: Merck Sharp & Dohme LLC
MK-0616 is an investigational, potentially first oral PCSK9 inhibitor designed to lower low density lipoprotein (LDL) cholesterol. Discovered and developed by Merck, MK-0616 is a macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors. MK-0616 is being developed under an agreement with UCB Pharmaceuticals. Results from the Phase IIb clinical trial evaluating MK-0616 showed that MK-0616 was generally well-tolerated with no overall trends across treatment groups in discontinuation rates or adverse events at week 16. No serious adverse events that were considered by the investigator to be related to treatment with MK-0616 were reported. Currently the drug is in Phase III stage for the treatment of Hypercholesterolemia.
* ARO-ANG 3: Arrowhead Pharmaceuticals
ARO-ANG3 is an investigational RNAi therapeutic designed to reduce expression of angiopoietin-like protein 3 (ANGPTL3), a hepatocyte expressed regulator of lipid and lipoprotein metabolism with multiple potential modes of action, including inhibition of lipoprotein lipase and endothelial lipase. Given the inhibitory role of ANGPTL3 in the metabolism of various lipoproteins and triglycerides, reduced expression and reduced circulating levels of ANGPTL3 may increase clearance of LDL-cholesterol, HDL-cholesterol, and triglycerides. Currently the drug is in Phase II stage for the treatment of Hypercholesterolemia.
* VXX-401: Vaxxinity, Inc.
VXX-401 was designed using Vaxxinity's proprietary synthetic peptide vaccine platform and is being developed for the treatment of hypercholesterolemia. The platform is designed to harness the immune system to convert the body into its own natural "drug factory," stimulating the production of antibodies. VXX-401 is designed to induce robust, long-acting antibodies against PCSK9 and lower LDL cholesterol to prevent or treat coronary heart disease. Currently the drug is in Phase I stage for the treatment of Hypercholesterolemia.
The Hypercholesterolemia Pipeline Report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Hypercholesterolemia with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypercholesterolemia Treatment.
* Hypercholesterolemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hypercholesterolemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypercholesterolemia market.
Learn more about Hypercholesterolemia Drugs opportunities in our groundbreaking Hypercholesterolemia research and development projects @ Hypercholesterolemia Unmet Needs [https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hypercholesterolemia Companies
Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics and others.
Hypercholesterolemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Hypercholesterolemia Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Hypercholesterolemia treatment by visiting our website. Stay informed about how we're transforming the future of Cardiovascular Diseases @ Hypercholesterolemia Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hypercholesterolemia Pipeline Report
* Coverage- Global
* Hypercholesterolemia Companies- Merck Sharp & Dohme LLC, Arrowhead Pharmaceuticals, Vaxxinity, Inc., Akeso Biopharma, Haisco Pharmaceutical Group Co., Ltd., Verve Therapeutics, Inc., Amytrx Therapeutics, EPIC BIO, Addpharma, NewAmsterdam Pharma, LIB Therapeutics and others.
* Hypercholesterolemia Pipeline Therapies- Gemcabene, Rosuvastatin calcium, KJX839, statins, ezetimibe, MK-0524A, ER Niacin and others.
* Hypercholesterolemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hypercholesterolemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Hypercholesterolemia Pipeline on our website @ Hypercholesterolemia Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/hypercholesterolemia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hypercholesterolemia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hypercholesterolemia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* MK-0616: Merck Sharp & Dohme LLC
* Mid Stage Products (Phase II)
* ARO-ANG 3: Arrowhead Pharmaceuticals
* Early Stage Products (Phase I)
* VXX-401: Vaxxinity, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Hypercholesterolemia Key Companies
* Hypercholesterolemia Key Products
* Hypercholesterolemia- Unmet Needs
* Hypercholesterolemia- Market Drivers and Barriers
* Hypercholesterolemia- Future Perspectives and Conclusion
* Hypercholesterolemia Analyst Views
* Hypercholesterolemia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypercholesterolemia-pipeline-appears-robust-with-25-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hypercholesterolemia-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypercholesterolemia Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4103579 • Views: …
More Releases from ABNewswire
Guillain-Barre Syndrome Market Set for Robust Growth Through 2034, Driven by Adv …
The Guillain-Barre Syndrome market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Annexon, Hansa Biopharma, Alexion Pharmaceuticals, and others. There is currently no FDA-approved drug specifically for Guillain-Barre syndrome, creating substantial opportunities for emerging therapies.
DelveInsight's "Guillain-Barre Syndrome Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=xpr]" report delivers an in-depth understanding of the Guillain-Barre Syndrome treatment market, historical and…
Ireland Data Center Market Revenue to Reach $4.45 Billion by 2030, Driven by AI, …
In-Depth Insights on 57 Existing Data Center Facilities Across Ireland - Arizton
According to the latest report by Arizton Advisory & Intelligence, Ireland data center market [https://www.arizton.com/market-reports/ireland-data-center-market-2025] is undergoing rapid transformation, powered by growing demand from hyperscale operators, surging AI adoption, and infrastructure modernization. The market is projected to grow at a CAGR of 9.79% between 2024 and 2030.
Report Scope:
Market Size (Investment): USD 4.45 Billion (2030)
Market Size (Area): 576 Thousand Sq.…
Online Payroll Services Modernized by IBN Technologies
IBN Technologies has launched upgraded online payroll services tailored for hybrid teams and global operations. The new solution offers secure cloud integration, real-time reporting, and automated compliance with multi-jurisdictional laborlabour laws. Serving industries from retail to healthcare, the platform enables error-free processing, reduces administrative load, and supports expansion into new markets.
Miami, Florida, 14 July 2025 - In response to the growing complexity of managing hybrid and geographically dispersed workforces, IBN…
IBN Technologies Powers Residential Civil Engineering with Cost-Efficient Models
IBN Technologies introduces a comprehensive suite of residential civil engineering services designed to help developers and construction firms improve project timelines, ensure code compliance, and reduce internal workload. With digital tools, certified workflows, and scalable support, the company delivers high-quality engineering solutions tailored for residential construction demands.
Miami, Florida, 14 July 2025 - As residential development accelerates globally, the need for agile, cost-effective, and technically sound engineering solutions has never been…
More Releases for Hypercholesterolemia
The Hypercholesterolemia Treatment Market to cling to the digitization
The Hypercholesterolemia Treatment Market is bound to witness a robust CAGR going forward. The present scenario is that of prediction of the course of treatment based on data analytics. Technology has been dominating in the form of IoMT (Internet-of-Medical-Things), AI (Artificial Intelligence), cloud computing, predictive analytics, and what not? With the proven advantage of the reduction in casualties and real-time access to the history of patients, and not to forget…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2017
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide “Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review”, H2 2017, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape.
Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension,…
Hypercholesterolemia Market Global Analysis & 2023 Forecast Report
Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol…
Hypercholesterolemia Market to Reflect Impressive Growth Rate by 2023
Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol…
Hypercholesterolemia Market - Global Industry Analysis 2020
Hypercholesterolemia is an inherited condition that results in high levels of total cholesterol. Cholesterol is a fatty substance that occurs naturally in the body that can be dangerous when it builds up on artery walls. Hypercholesterolemia can cause atherosclerosis and increase your risk of heart disease called coronary artery disease. Human blood cholesterol includes of high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and very low-density lipoprotein (VLDL) cholesterol.
Get a…
